Show simple item record

dc.contributor.authorBehrens, Georg M N
dc.contributor.authorCossmann, Anne
dc.contributor.authorStankov, Metodi V
dc.contributor.authorSchulte, Bianca
dc.contributor.authorStreeck, Hendrik
dc.contributor.authorFörster, Reinhold
dc.contributor.authorBosnjak, Berislav
dc.contributor.authorWillenzon, Stefanie
dc.contributor.authorBoeck, Anna-Lena
dc.contributor.authorThu Tran, Anh
dc.contributor.authorThiele, Thea
dc.contributor.authorGraalmann, Theresa
dc.contributor.authorKayser, Moritz Z
dc.contributor.authorZychlinsky Scharff, Anna
dc.contributor.authorDopfer, Christian
dc.contributor.authorHorke, Alexander
dc.contributor.authorPink, Isabell
dc.contributor.authorWitte, Torsten
dc.contributor.authorWetzke, Martin
dc.contributor.authorErnst, Diana
dc.contributor.authorJablonka, Alexandra
dc.contributor.authorHapple, Christine
dc.date.accessioned2020-09-24T14:13:42Z
dc.date.available2020-09-24T14:13:42Z
dc.date.issued2020-09-04
dc.identifier.citationnfect Dis Ther. 2020 Sep 4:1–13. doi: 10.1007/s40121-020-00334-1. Epub ahead of print. PMID: 32886335.en_US
dc.identifier.issn2193-8229
dc.identifier.pmid32886335
dc.identifier.doi10.1007/s40121-020-00334-1
dc.identifier.urihttp://hdl.handle.net/10033/622458
dc.description.abstractBackground: Serology testing is explored for epidemiological research and to inform individuals after suspected infection. During the coronavirus disease 2019 (COVID-19) pandemic, frontline healthcare professionals (HCP) may be at particular risk for infection. No longitudinal data on functional seroconversion in HCP in regions with low COVID-19 prevalence and low pre-test probability exist. Methods: In a large German university hospital, we performed weekly questionnaire assessments and anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G (IgG) measurements with various commercial tests, a novel surrogate virus neutralisation test, and a neutralisation assay using live SARS-CoV-2. Results: From baseline to week 6, 1080 screening measurements for anti-SARS CoV-2 (S1) IgG from 217 frontline HCP (65% female) were performed. Overall, 75.6% of HCP reported at least one symptom of respiratory infection. Self-perceived infection probability declined over time (from mean 20.1% at baseline to 12.4% in week 6, p < 0.001). In sera of convalescent patients with PCR-confirmed COVID-19, we measured high anti-SARS-CoV-2 IgG levels, obtained highly concordant results from enzyme-linked immunosorbent assays (ELISA) using e.g. the spike 1 (S1) protein domain and the nucleocapsid protein (NCP) as targets, and confirmed antiviral neutralisation. However, in HCP the cumulative incidence for anti-SARS-CoV-2 (S1) IgG was 1.86% for positive and 0.93% for equivocal positive results over the study period of 6 weeks. Except for one HCP, none of the eight initial positive results were confirmed by alternative serology tests or showed in vitro neutralisation against live SARS-CoV-2. The only true seroconversion occurred without symptoms and mounted strong functional humoral immunity. Thus, the confirmed cumulative incidence for neutralizing anti-SARS-CoV-2 IgG was 0.47%. Conclusion: When assessing anti-SARS-CoV-2 immune status in individuals with low pre-test probability, we suggest confirming positive results from single measurements by alternative serology tests or functional assays. Our data highlight the need for a methodical serology screening approach in regions with low SARS-CoV-2 infection rates.en_US
dc.language.isoenen_US
dc.publisherSpringer Healthcareen_US
dc.rightsAttribution-NonCommercial-ShareAlike 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectCOVID-19en_US
dc.subjectCoronavirusen_US
dc.subjectHealthcare professionalsen_US
dc.subjectHumoral immunityen_US
dc.subjectInfectionen_US
dc.subjectPandemicen_US
dc.subjectSARS-CoV-2en_US
dc.subjectSerological testingen_US
dc.subjectVirusen_US
dc.titleStrategic Anti-SARS-CoV-2 Serology Testing in a Low Prevalence Setting: The COVID-19 Contact (CoCo) Study in Healthcare Professionals.en_US
dc.typeArticleen_US
dc.contributor.departmentTWINCORE, Zentrum für experimentelle und klinische Infektionsforschung GmbH,Feodor-Lynen Str. 7, 30625 Hannover, Germany.en_US
dc.identifier.journalInfectious diseases and therapyen_US
refterms.dateFOA2020-09-24T14:13:43Z
dc.source.journaltitleInfectious diseases and therapy
dc.source.countryNew Zealand


Files in this item

Thumbnail
Name:
Behrens et al.pdf
Size:
1.801Mb
Format:
PDF
Description:
Open Access publication

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-ShareAlike 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-ShareAlike 4.0 International